Harrow Health, Inc.
General ticker "HROW" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $1.5B (TTM average)
Harrow Health, Inc. follows the US Stock Market performance with the rate: 18.4%.
Estimated limits based on current volatility of 3.6%: low 42.49$, high 45.67$
Factors to consider:
- Total employees count: 315 (+45.2%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: FDA approval delays, Regulatory and compliance, Manufacturing disruptions, Sales infrastructure, Capital access
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [30.39$, 57.86$]
- 2026-12-31 to 2027-12-31 estimated range: [24.58$, 48.83$]
Financial Metrics affecting the HROW estimates:
- Negative: with PPE of 107.5 at the end of fiscal year the price was high
- Positive: 7.57 < Operating profit margin, % of 11.21
- Positive: -3.72 < Return on assets ratio (scaled to [-100,100]) of -1.27
- Positive: Industry inventory ratio change (median), % of 0.12 <= 0.28
- Positive: Investing cash flow per share per price, % of -0.31 > -0.60
- Positive: Interest expense per share per price, % of 1.36 <= 3.34
- Positive: -0.03 < Operating cash flow per share per price, % of 2.47
- Negative: Shareholder equity ratio, % of 13.13 <= 19.19
Short-term HROW quotes
Long-term HROW plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $130.19MM | $199.61MM | $272.30MM |
| Operating Expenses | $129.76MM | $190.79MM | $241.79MM |
| Operating Income | $0.43MM | $8.82MM | $30.52MM |
| Non-Operating Income | $-24.14MM | $-26.14MM | $-31.88MM |
| Interest Expense | $21.32MM | $22.79MM | $24.18MM |
| R&D Expense | $6.65MM | $12.23MM | $20.94MM |
| Income(Loss) | $-23.71MM | $-17.32MM | $-1.37MM |
| Taxes | $0.70MM | $0.16MM | $3.77MM |
| Net Income(Loss)* | $-24.41MM | $-17.48MM | $-5.14MM |
| Stockholders Equity | $70.77MM | $69.65MM | $52.45MM |
| Inventory | $10.87MM | $10.70MM | $13.52MM |
| Assets | $312.16MM | $388.97MM | $399.48MM |
| Operating Cash Flow | $3.84MM | $-22.20MM | $43.86MM |
| Capital expenditure | $152.55MM | $38.67MM | $1.10MM |
| Investing Cash Flow | $-152.55MM | $-33.16MM | $-5.46MM |
| Financing Cash Flow | $126.53MM | $28.53MM | $-12.72MM |
| Earnings Per Share** | $-0.75 | $-0.49 | $-0.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.